<Blinded Review: TIME_ANON_0342>
**Composite Score:** 3.6 / 10.0 (Rigor: 1.1/3.5 | Claims: 1.0/2.5 | Biology: 0.8/2.0 | Reproducibility: 0.7/2.0)
**Bias Category:** Technical/Assay
**Verdict:** Reject (Fundamental Flaws)
**Study Modality:** Hybrid Computational + Wet-Lab
**Technology Maturity:** Commodity/Hype-Cycle Template
**Epistemic Stage:** Translational/Preclinical/Biomarker

---

### 1. Executive Summary
This study follows a formulaic "lncRNA–$\text{m}^6\text{A}$ reader–target mRNA" oncology template in non-small cell lung cancer (NSCLC), proposing that the pseudogene-derived lncRNA `RP11-480I12.5` (specifically transcript `002`) interacts with the $\text{m}^6\text{A}$ reader protein `IGF2BP3` to stabilize `WDHD1` mRNA, thereby promoting proliferation and inhibiting cisplatin-induced apoptosis in `H1650` and `Calu-1` cells. The authors query public web portals (`GEPIA2`, `CPTAC`, `SRAMP`, `m6A2Target`, `Enrichr`), perform RT-qPCR, FISH/IF colocalization, lentiviral shRNA knockdown of `RP11-480I12.5` and `IGF2BP3`, siRNA knockdown of `WDHD1`, CCK-8, colony formation, Annexin-V/7AAD apoptosis, RIP, desthiobiotinylated RNA pull-down, and Actinomycin D mRNA decay assays.

Despite the superficially complete array of standard cell-line assays, a close forensic reading of the Methods and Results reveals multiple severe technical errors, self-contradictory screening thresholds, misattributed reagent catalog numbers, a backwards RNA pull-down protocol description, absence of normal lung epithelial controls, and complete lack of epistatic rescue experiments or direct $\text{m}^6\text{A}$ validation (e.g., MeRIP-qPCR).

### 2. Methodological & Statistical Audit
- **Reversed Inequality Signs in Bioinformatic Screening Criteria:** In the Methods ("Bioinformatics analysis", line 36), the authors state: *"The screening criteria for lncRNA RP11-480I12.5 were set at $|\log_2\text{FC}| \le 0.5$ and $P < 0.01$, whereas its four transcripts (001, 002, 003, 004), along with IGF2BP3 and WDHD1, were screened under criteria of $|\log_2\text{FC}| \le 1$ and $P < 0.05$."* Filtering for $|\log_2\text{FC}| \le 0.5$ or $\le 1$ selects genes with *no* fold change rather than differentially expressed genes ($|\log_2\text{FC}| \ge 0.5$ or $\ge 1$).
- **Fabricated / Copy-Pasted Catalog Number for CCK-8 Assay Kit:** In the "Cell viability assay" section (line 91), the authors state that cellular viability was measured using *"the CCK8 assay kit (15596026, Invitrogen, CA, USA)."* However, in line 52 ("RT-qPCR"), catalog number `15596026, Invitrogen, CA, USA` was already cited as **TRIzol Reagent** (which is indeed Invitrogen's real catalog number for TRIzol). Invitrogen does not sell a CCK-8 kit under its TRIzol catalog number.
- **Physiologically Implausible Cisplatin Concentration (`5 µg/L`):** In the "Cell apoptosis" section (line 101), the authors report treating `H1650` and `Calu-1` cells with cisplatin at **`5 µg/L`** ($5\,\text{ng/mL} \approx 16.7\,\text{nM}$) for 24 h. Standard cytotoxic cisplatin concentrations in NSCLC 24-hour apoptosis assays are $5\,\mu\text{g/mL}$ ($5\,\text{mg/L}$, 1,000-fold higher); $16.7\,\text{nM}$ cisplatin is sub-pharmacological and does not induce acute 24-hour apoptosis in NSCLC lines.
- **Backwards RNA Pull-Down Fraction Analyzed by Western Blot:** In the "RNA pull-down" section (line 111), after incubating cell lysates with desthiobiotin-labeled RNA bound to streptavidin magnetic beads for 1 h, the authors state: *"The supernatant was removed and stored for western blot analysis."* In an affinity pull-down assay, the unbound supernatant contains flow-through proteins that *failed* to bind the RNA; Western blotting must be performed on the washed, eluted bead-bound fraction (alongside an input control and an antisense RNA negative control, neither of which is described in the Methods).
- **Absence of Normal Lung Epithelial Control Cell Line and Single-shRNA Confounding:** In Fig. 3A, the authors claim that "qPCR analysis revealed the overexpression of RP11-480I12.5 along with its transcript 002 in NSCLC cells," yet they only profile four NSCLC tumor lines (`A549`, `H1299`, `H1650`, `Calu-1`) without any non-malignant bronchial epithelial control line (such as `BEAS-2B` or `16HBE`). Furthermore, `RP11-480I12.5` knockdown uses only a single shRNA construct (`shRP11`) without a second independent hairpin to rule out off-target seed effects.
- **Misuse of One-Way ANOVA on Two-Variable Time-Course and Drug Combination Designs:** In Fig. 4A–B (CCK-8 across 0, 24, 48, 72 h), Fig. 4D–F (`shNC` vs. `shRP11`/`shIGF2BP3` $\times$ $\pm$ cisplatin), and Fig. 5E / 6H–I (Actinomycin D decay across 0, 3, 6, 12, 24 h), the authors apply unpaired two-group $t$-tests or one-way ANOVA instead of two-way repeated-measures or factorial ANOVA.

### 3. Biological / Experimental Grounding & Claim Proportionality
- **[Moderately Supported]** Public TCGA/CPTAC datasets show elevated `IGF2BP3` and `WDHD1` mRNA and protein expression in LUAD and LUSC compared to normal lung tissue.
- **[Fragile]** The claim that `IGF2BP3` stabilizes `RP11-480I12.5` via $\text{m}^6\text{A}$ modification is based solely on sequence motif prediction (`SRAMP`); no MeRIP-qPCR ($\text{m}^6\text{A}$-RIP), `METTL3/14` depletion, or $\text{m}^6\text{A}$-site point mutation (`GGACU` $\to$ `GUACU`) was performed.
- **[Overstated]** The central mechanistic claim that the `RP11-480I12.5`–`IGF2BP3` complex promotes NSCLC proliferation and anti-apoptosis *by* upregulating `WDHD1` is never tested via epistatic rescue (e.g., ectopically restoring `WDHD1` in `shRP11` or `shIGF2BP3` cells, or knocking down `WDHD1` in `RP11-480I12.5`-overexpressing cells), nor is direct binding of `RP11-480I12.5` or `IGF2BP3` to `WDHD1` mRNA demonstrated by RIP/pull-down.

### 4. Reproducibility & Data Completeness
- **Strengths:** shRNA and siRNA sequences are provided in the Methods text.
- **Deficiencies:** RT-qPCR primers (`Table S1`) and FISH probe sequences (`Table S2`) are relegated to supplementary files not included in the manuscript; no raw Western blot membranes or flow cytometry gating plots are provided; catalog numbers and protocol descriptions contain severe errors (`15596026` for CCK-8, `5 µg/L` cisplatin, RNA pull-down supernatant); data availability is restricted to "available on request."
</Blinded Review: TIME_ANON_0342>
